Literature DB >> 23543565

Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections.

Jennifer Shiu1, Erica Wang, Aaron M Tejani, Michael Wasdell.   

Abstract

BACKGROUND: Intravenous broad-spectrum antibiotics are indicated for the treatment of severe infections. However, the emergence of infections caused by multi-drug resistant organisms in conjunction with a lack of novel antibiotics has prompted the investigation of alternative dosing strategies to improve clinical efficacy and tolerability. To optimise pharmacokinetic and pharmacodynamic antibiotic parameters, continuous antibiotic infusions have been compared to traditional intermittent antibiotic infusions.
OBJECTIVES: To compare the clinical efficacy and safety of continuous intravenous administration of concentration-dependent and time-dependent antibiotics to traditional intermittent intravenous administration in adults with severe acute bacterial infections. SEARCH
METHODS: The following electronic databases were searched in September 2012: The Cochrane Injuries Group Specialised Register, Cochrane Central Register of Controlled Trials (The Cochrane Library), MEDLINE (OvidSP), EMBASE (OvidSP), CINAHL, ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED), ISI Web of Science: Conference Proceedings Citation Index-Science (CPCI-S). The reference lists of all relevant material, the Internet and the trials registry www.clinicaltrials.gov for completed and ongoing trials were also searched. SELECTION CRITERIA: Randomized controlled trials in adults with a bacterial infection requiring intravenous antibiotic therapy comparing continuous versus intermittent infusions of antibiotics were included. Both time-dependent and concentration-dependent antibiotics were considered. DATA COLLECTION AND ANALYSIS: Three independent authors performed data extraction for the included studies. All data was cross-checked and disagreements resolved by consensus. An intention to treat analysis was conducted using a random-effects model. MAIN
RESULTS: Twenty-nine studies met inclusion criteria with a combined total of over 1,600 patients. The majority of included studies were judged to be at unclear or high risk of bias with regard to randomisation sequence generation, allocation concealment, blinding, management of incomplete outcome data, selective outcome reporting, and other potential threats to validity. No studies were judged to be at low risk of bias for all methodological quality items assessed. There were no differences in all-cause mortality (n=1241, RR 0.89, 95% CI 0.67 - 1.20, p=0.45), infection recurrence (n=398, RR 1.22, 95% CI 0.35 - 4.19, p=0.76), clinical cure (n=975, RR 1.00, 95% CI 0.93 - 1.08, p=0.98), and superinfection post-therapy (n=813, RR 1.08, 95% CI 0.60 - 1.94, p=0.79). There were no differences in safety outcomes including adverse events (n=575, RR 1.02, 95% CI 0.94 - 1.12, p=0.63), serious adverse events (n=871, RR 1.36, 95% CI 0.80 - 2.30, p=0.26), and withdrawal due to adverse events (n=871, RR 2.03, 95% CI 0.52 - 7.95, p=0.31). A difference was observed in the subgroup analyses of clinical cure in septic versus non-septic patients, where intermittent antibiotic infusions were favoured for clinical cure in septic patients. However, this effect was not consistent between random-effects and fixed-effects analyses. No differences were found in sensitivity analyses conducted. AUTHORS'
CONCLUSIONS: There were no differences in mortality, infection recurrence, clinical cure, superinfection post-therapy, and safety outcomes when comparing continuous infusions of intravenous antibiotics to traditional intermittent infusions of antibiotics. However, the wide confidence intervals suggest that beneficial or harmful effects cannot be ruled out for all outcomes. Therefore, the current evidence is insufficient to recommend the widespread adoption of continuous infusion antibiotics in the place of intermittent infusions of antibiotics. Further large prospective randomised trials, with consistent and complete reporting of clinical outcome measures, conducted with concurrent pharmacokinetic and pharmacodynamic studies in special populations are required to determine whether adoption of continuous antibiotic infusions is warranted in specific circumstances.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23543565      PMCID: PMC8946287          DOI: 10.1002/14651858.CD008481.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  85 in total

1.  Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis.

Authors:  Annette Lubasch; Stefan Lück; Hartmut Lode; Harald Mauch; Joachim Lorenz; Pal Bölcskei; Tobias Welte
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

2.  Should IV Antibiotics Be Administered by Prolonged Infusion?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2010-05

3.  Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.

Authors:  Sutep Jaruratanasirikul; Somchai Sriwiriyajan; Jarurat Punyo
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  [A preliminary study of the administration of carbapenem antibiotics in sepsis patients on the basis of the administration time].

Authors:  Masahiro Kojika; Nobuhiro Sato; Masanori Hakozaki; Yasusi Suzuki; Gaku Takahasi; Sigeatu Endo; Kenji Suzuki; Go Wakabayasi
Journal:  Jpn J Antibiot       Date:  2005-10

5.  Serum concentrations of cefuroxime after continuous infusion in coronary bypass graft patients.

Authors:  S E Pass; C I Miyagawa; D P Healy; T D Ivey
Journal:  Ann Pharmacother       Date:  2001-04       Impact factor: 3.154

6.  Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.

Authors:  D P Nicolau; C H Nightingale; M A Banevicius; Q Fu; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

7.  A pilot study to determine the feasibility of continuous cefazolin infusion.

Authors:  Todd Waltrip; Robert Lewis; Vyvy Young; Martin Farmer; Susan Clayton; Steven Myers; Laman A Gray; Susan Galandiuk
Journal:  Surg Infect (Larchmt)       Date:  2002       Impact factor: 2.150

Review 8.  Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients?

Authors:  Jason A Roberts; Jeffrey Lipman; Stijn Blot; Jordi Rello
Journal:  Curr Opin Crit Care       Date:  2008-08       Impact factor: 3.687

9.  Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.

Authors:  Peggy S McKinnon; Joseph A Paladino; Jerome J Schentag
Journal:  Int J Antimicrob Agents       Date:  2008-03-04       Impact factor: 5.283

10.  Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.

Authors:  Ivan Chytra; Martin Stepan; Jan Benes; Petr Pelnar; Alexandra Zidkova; Tamara Bergerova; Richard Pradl; Eduard Kasal
Journal:  Crit Care       Date:  2012-06-28       Impact factor: 9.097

View more
  19 in total

1.  Continuous versus short-term infusion of cefuroxime: assessment of concept based on plasma, subcutaneous tissue, and bone pharmacokinetics in an animal model.

Authors:  Mikkel Tøttrup; Bo M Bibby; Tore F Hardlei; Mats Bue; Sigrid Kerrn-Jespersen; Kurt Fuursted; Kjeld Søballe; Hanne Birke-Sørensen
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

Review 2.  [Antibiotic dosing for renal function disorders and continuous renal replacement therapy].

Authors:  Erik Michael; Detlef Kindgen-Milles
Journal:  Anaesthesist       Date:  2015-04       Impact factor: 1.041

3.  Should Prolonged Infusion of β-Lactams Become Standard of Practice?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2017 Mar-Apr

4.  After standard dosage of piperacillin plasma concentrations of drug are subtherapeutic in burn patients.

Authors:  Katharina Olbrisch; Tobias Kisch; Julia Thern; Evelyn Kramme; Jan Rupp; Tobias Graf; Sebastian G Wicha; Peter Mailänder; Walter Raasch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-10-27       Impact factor: 3.000

5.  Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearance.

Authors:  Stephen Y Liang; Anand Kumar
Journal:  Curr Infect Dis Rep       Date:  2015-07       Impact factor: 3.725

6.  Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.

Authors:  Mohd H Abdul-Aziz; Helmi Sulaiman; Mohd-Basri Mat-Nor; Vineya Rai; Kang K Wong; Mohd S Hasan; Azrin N Abd Rahman; Janattul A Jamal; Steven C Wallis; Jeffrey Lipman; Christine E Staatz; Jason A Roberts
Journal:  Intensive Care Med       Date:  2016-01-11       Impact factor: 17.440

7.  Single-Center Pharmacokinetic Study and Simulation of a Low Meropenem Concentration in Brain-Dead Organ Donors.

Authors:  Jae-Myeong Lee; Joo Won Lee; Tae Seok Jeong; Eun Sook Bang; So Hee Kim
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

Review 8.  Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.

Authors:  Mordechai Grupper; Joseph L Kuti; David P Nicolau
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

9.  Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.

Authors:  Tamar F Barlam; Sara E Cosgrove; Lilian M Abbo; Conan MacDougall; Audrey N Schuetz; Edward J Septimus; Arjun Srinivasan; Timothy H Dellit; Yngve T Falck-Ytter; Neil O Fishman; Cindy W Hamilton; Timothy C Jenkins; Pamela A Lipsett; Preeti N Malani; Larissa S May; Gregory J Moran; Melinda M Neuhauser; Jason G Newland; Christopher A Ohl; Matthew H Samore; Susan K Seo; Kavita K Trivedi
Journal:  Clin Infect Dis       Date:  2016-04-13       Impact factor: 9.079

Review 10.  [Therapeutic drug monitoring and individual dosing of antibiotics during sepsis : Modern or just "trendy"?]

Authors:  A Brinkmann; A C Röhr; A Köberer; T Fuchs; J Preisenberger; W A Krüger; O R Frey
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-09-13       Impact factor: 0.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.